Wedbush restated their outperform rating on shares of Arvinas (NASDAQ:ARVN - Free Report) in a report published on Tuesday,RTT News reports. They currently have a $57.00 target price on the stock. Wedbush also issued estimates for Arvinas' Q1 2025 earnings at ($0.93) EPS, Q2 2025 earnings at ($0.94) EPS, Q3 2025 earnings at ($0.95) EPS, Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($3.75) EPS, FY2026 earnings at ($3.17) EPS, FY2027 earnings at ($3.30) EPS, FY2028 earnings at ($3.51) EPS and FY2029 earnings at ($1.15) EPS.
Several other equities research analysts also recently issued reports on ARVN. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Arvinas in a research note on Friday, February 7th. Guggenheim reissued a "buy" rating on shares of Arvinas in a report on Thursday, December 12th. BMO Capital Markets decreased their price objective on shares of Arvinas from $90.00 to $88.00 and set an "outperform" rating for the company in a report on Wednesday, November 20th. Oppenheimer decreased their price objective on shares of Arvinas from $50.00 to $40.00 and set an "outperform" rating for the company in a report on Thursday, October 31st. Finally, HC Wainwright reissued a "buy" rating and set a $87.00 price objective on shares of Arvinas in a report on Wednesday, December 11th. Thirteen analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $60.00.
Get Our Latest Research Report on ARVN
Arvinas Price Performance
Arvinas stock traded up $0.64 during midday trading on Tuesday, hitting $18.31. 935,305 shares of the stock were exchanged, compared to its average volume of 823,758. Arvinas has a 1 year low of $16.61 and a 1 year high of $53.08. The firm has a market cap of $1.26 billion, a P/E ratio of -3.92 and a beta of 1.88. The company has a 50 day moving average price of $18.88 and a two-hundred day moving average price of $23.22.
Arvinas (NASDAQ:ARVN - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.44. During the same quarter in the previous year, the company posted ($2.53) EPS. As a group, analysts predict that Arvinas will post -3.22 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of ARVN. nVerses Capital LLC acquired a new position in shares of Arvinas in the 3rd quarter valued at about $39,000. KBC Group NV boosted its stake in Arvinas by 77.0% during the 4th quarter. KBC Group NV now owns 2,885 shares of the company's stock valued at $55,000 after purchasing an additional 1,255 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in Arvinas by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company's stock valued at $61,000 after purchasing an additional 440 shares during the period. Quantbot Technologies LP boosted its stake in Arvinas by 147.3% during the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company's stock valued at $108,000 after purchasing an additional 2,601 shares during the period. Finally, Exchange Traded Concepts LLC boosted its stake in Arvinas by 37.0% during the 3rd quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company's stock valued at $164,000 after purchasing an additional 1,798 shares during the period. 95.19% of the stock is owned by institutional investors and hedge funds.
Arvinas Company Profile
(
Get Free Report)
Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
See Also
Before you consider Arvinas, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arvinas wasn't on the list.
While Arvinas currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
